Nutrition delivery of a model-based ICU glycaemic control system. by Stewart KW et al.
Stewart et al. Ann. Intensive Care  (2018) 8:4 
https://doi.org/10.1186/s13613-017-0351-9
RESEARCH
Nutrition delivery of a model-based ICU 
glycaemic control system
Kent W. Stewart1* , J. Geoffrey Chase1, Christopher G. Pretty1 and Geoffrey M. Shaw2
Abstract 
Background: Hyperglycaemia is commonplace in the adult intensive care unit (ICU), associated with increased 
morbidity and mortality. Effective glycaemic control (GC) can reduce morbidity and mortality, but has proven difficult. 
STAR is a proven, effective model-based ICU GC protocol that uniquely maintains normo-glycaemia by changing both 
insulin and nutrition interventions to maximise nutrition in the context of GC in the 4.4–8.0 mmol/L range. Hence, the 
level of nutrition it provides is a time-varying estimate of the patient-specific ability to take up glucose.
Methods: First, the clinical provision of nutrition by STAR in Christchurch Hospital, New Zealand (N = 221 Patients) is 
evaluated versus other ICUs, based on the Cahill et al. survey of 158 ICUs. Second, the inter- and intra- patient variation 
of nutrition delivery with STAR is analysed. Nutrition rates are in terms of percentage of caloric goal achieved.
Results: Mean nutrition rates clinically achieved by STAR were significantly higher than the mean and best ICU sur-
veyed, for the first 3 days of ICU stay. There was large inter-patient variation in nutrition rates achieved per day, which 
reduced overtime as patient-specific metabolic state stabilised. Median intra-patient variation was 12.9%; however, 
the interquartile range of the mean per-patient nutrition rates achieved was 74.3–98.2%, suggesting patients do not 
deviate much from their mean patient-specific nutrition rate. Thus, the ability to tolerate glucose intake varies signifi-
cantly between, rather than within, patients.
Conclusions: Overall, STAR’s protocol-driven changes in nutrition rate provide higher nutrition rates to hyperglycae-
mic patients than those of 158 ICUs from 20 countries. There is significant inter-patient variability between patients 
to tolerate and uptake glucose, where intra-patient variability over stay is much lower. Thus, a best nutrition rate is 
likely patient specific for patients requiring GC. More importantly, these overall outcomes show high nutrition delivery 
and safe, effective GC are not exclusive and that restricting nutrition for GC does not limit overall nutritional intake 
compared to other ICUs.
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Background
The ICU patient is under considerable physiological 
stress, resulting in 20–40% of patients experiencing dys-
regulation of blood glucose (BG) levels [1] and hyper-
glycaemia [2, 3], which is associated with increased 
morbidity and mortality [4–6]. Glycaemic variability 
due to poor control [7] has also been independently 
associated with mortality [7–10]. Effective glycaemic 
control (GC) can reduce mortality and morbidity [11–
14], organ failure [15] and cost of care [16, 17]. However, 
due to inter- and intra- patient variability [18–21], GC 
has proven difficult, and many protocols have increased 
hypoglycaemia, also associated with increased mortality 
[22–25], due to the inability to provide consistent, safe 
and effective GC [25–31].
The model-based STAR (Stochastic TARgeted) proto-
col has proven to be safe, consistent and effective [32, 33]. 
The tablet-based STAR protocol uses a clinically evalu-
ated [34, 35] physiological insulin–glucose model [36, 37] 
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in conjunction with a stochastic model of metabolic vari-
ability [38, 39], to estimate a patient-specific current met-
abolic state and its potential future variability [40, 41]. 
Thus, treatments are selected by forward simulation with 
a clinically specified desired risk of light hypoglycaemia 
(5% BG < 4.4 mmol/L) due to these possible future varia-
tions. STAR has proven to be safe, effective and replicable 
across ICUs [32].
Uniquely, STAR maintains normal BG levels by chang-
ing both insulin and nutrition interventions [33]. Chang-
ing nutrition interventions differentiates STAR from 
other ICU GC protocols [42], as most only change insulin 
interventions (e.g. [43–47]). STAR maximises nutrition 
in the context of GC in the 4.4–8.0  mmol/L range [33, 
40]. Hence, the level of nutrition it provides is a patient-
specific, time-varying estimate of the ability to take up 
glucose and is reduced in the face of significant insulin 
resistance.
Currently, there is also significant debate over the 
appropriate amount to feed an ICU patient. Many stud-
ies have shown mixed results in reviewing caloric intake, 
route, and timing and their relation to outcome [48–58]. 
Cahill et  al. [59] surveyed the overall nutrition perfor-
mance of 158 ICUs, from 20 countries, finding significant 
variation in nutrition delivery. This study also found an 
ideal relation to mortality at 85% of the caloric goal nutri-
tion rate set by the respective ICU [51], based on a model 
fit to the large collection of retrospective survey data 
obtained from 158 ICUs in 20 countries. This ‘Heyland 
ideal’ value and the best performing unit surveyed are 
used in this study as a guideline for assessing the clinical 
performance of STAR nutrition delivery.
This paper first evaluates the clinical provision of 
nutrition by STAR, to a cohort of hyperglycaemic ICU 
patients, versus all ICU patients in other ICUs based on 
the survey results of Cahill et  al. [59] to assess if safe, 
effective GC precludes or limits high nutrition delivery, 
as well as determining if nutrition restriction to obtain 
GC limits total nutritional intake. Second, the inter- 
and intra- patient variation of nutritional delivery, while 
maintaining normo-glycaemia, is assessed to evaluate a 
range of glucose/nutrition tolerance in ICU patients on 
GC. The main outcomes assess clinically provided nutri-
tion using STAR at the cohort level in an international 
context and then show a best nutrition rate is likely 




Starting criteria for STAR is two successive BG measure-
ments over 8.0  mmol/L within a 4-h period. After two 
measurements are taken, integral-based parameter fitting 
[60] is used to identify a clinically evaluated model-based 
insulin sensitivity [34–36]. This value is used with a sto-
chastic model, based on historical data, [33, 38, 39, 61] to 
find the 5th and 95th percentile potential future insulin 
sensitivity values. These 5th and 95th percentile insulin 
sensitivity values and a potential insulin and nutrition 
intervention are then used to forward-simulate the likely 
resulting 5th and 95th percentile BG values for that inter-
vention to find the intervention with 5% risk of BG < 4.4–
4.6 mmol/L [33, 40]. Full details can be found in [33].
STAR modifies nutrition rate depending on the bounds 
of predicted potential behaviour, with a preference to 
increase insulin before reducing nutrition, and to raise 
nutrition whenever possible [33, 40]. STAR modulates 
this nutrition rate between 30 and 100% of the caloric 
goal, with a maximum step change of ± 30% caloric goal 
per hour [33]. ACCP guidelines are used to determine 
patient-specific daily caloric goal intake of 25 kcal/kg/day 
[62].
Overall, STAR attempts to provide the maximum nutri-
tion rate a patient can tolerate while safely keeping BG in 
the 4.4–8.0  mmol/L range. However, insulin saturation 
limits the impact of insulin to lower BG levels on its own 
[63–65], requiring nutrition restriction in some patients 
or time periods. Hence, based on STAR’s control predic-
tions, providing excess carbohydrates to a patient above 
this limit would result in excess BG. Therefore, the nutri-
tion rate achieved by STAR represents a ‘STAR ideal’ 
patient-specific nutrition rate that maximises their likeli-
hood of falling within the targeted 4.4–8.0  mmol/L BG 
band, based on their current ability to tolerate glucose.
Christchurch clinical implementation
Clinical data from 221 hyperglycaemic ICU patients 
treated with STAR (2011–2015) [32] in the Christch-
urch Hospital ICU (mixed medical surgical) were used 
to assess the performance of its variable nutrition deliv-
ery. BG, insulin and nutrition data were collected from 
STAR tablets and thus only exists when patients are on 
GC. STAR has proven to provide excellent GC in this 
cohort spending over 88% time, per patient, in the tar-
geted 4.4–8.0 mmol/L range, as shown in Table 1. STAR 
patients in Christchurch are typically fed enterally with 
the low carbohydrate Glucerna™ Select (74.6 g/L Carbo-
hydrate, 50 g/L Protein, 21.1 g/L Fibre, Abbott Labs, Illi-
nois, USA), where carbohydrate concentrations exclude 
indigestible fibre. Parenteral nutrition (PN) is used occa-
sionally, at clinician discretion, to supplement enteral 
nutrition. While STAR knows of the PN value, it does not 
regulate it and will still try to provide 100% of the caloric 
goal through enteral nutrition (EN). Thus, enabling the 
possibility of nutrition delivery over 100% of goal. Cohort 
demographics are given in Table 1.
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Patients are not weighed in the Christchurch ICU, so 
ACCP caloric goal feed is approximated by estimating the 
patient weight. This estimation first assumes an 80 kg indi-
vidual and then modifies this value based on frame size 
(subjective assessment; small, medium, large), age and sex, 
using Table 2 and Eq. 1 [66].
Equation  1 modifies the goal feed rate of 25  kcal/kg/day 
into a maximum range of 1152–2420  kcal/day. In this 
cohort, the median interquartile range (IQR) goal feed rate 
was 1800 [1608–1992] kcal/day. Due to clinical circum-
stances, such as planned surgery requiring a fasted state, 
medical imaging,  and/or gastric tolerances, a patient’s 
(1)A ∗ F ∗ G ∗ 80 ∗ 25 = kcal Goal/Day
nutrition may be stopped or reduced significantly, for 
short periods, not reflective of the STAR feeding algo-
rithm. In this analysis, all occurrences of feeding less than 
30% caloric goal are ignored (3,135 h, 14.4% of the time).
Ethics, consent and permissions
STAR is the standard of care in Christchurch Hospital, 
New Zealand; therefore, no consent was required from 
patients to be placed on the STAR GC protocol. The 
Upper South Regional Ethics Committee, New Zealand, 
granted approval for the audit, analysis and publication of 
the retrospective data.
Analysis
Overall clinical performance of current STAR variable 
nutrition protocol
The mean cohort caloric goal achieved per day in the 
ICU by STAR, with hyperglycaemic ICU patients, is cal-
culated and compared to the entire ICU patient cohorts 
reviewed by Cahill et al. [59]. For STAR, information only 
exists for periods of GC, which are aligned to the appro-
priate day of ICU stay so comparisons to Cahill et al. [59] 
are valid. The percentage of caloric goal achieved repre-
sents the total caloric intake (including protein calories) 
from both EN and PN, in regard to the ACCP caloric 
goal. This analysis helps answer whether caloric restric-
tion for GC, or safe, effective GC in general, preclude or 
limit nutrition delivery when compared to that achieved 
by the entire ICU patient cohort.
Per‑patient nutrition delivery
The distribution per patient (median, IQR, 5th–95th 
range) of caloric goal achieved per day on STAR is cal-
culated. The per-day distribution is compared to the best 
performing ICU surveyed in [59] and the 85% ‘Heyland 
ideal’ caloric goal presented in [51] to evaluate the per-
centage of patients who can tolerate more, or less, nutri-
tion than these results. This comparison delineates the 
range and distribution of glucose and nutrition tolerance 
for these medical ICU patients.
The mean and variation of caloric goal achieved over a 
patient’s entire stay is assessed in terms of median IQR 
between patients and to the overall variation seen per day 
across the entire cohort. This assesses if the overall vari-
ability seen per day is due to variable patients or different 
patient-specific tolerances of nutritional uptake.
Results
Overall clinical performance of current STAR variable 
nutrition protocol
The percentage caloric goal clinically achieved by STAR, 
each day in ICU, was compared to the survey results in 
Cahill et al. [59]. Figure 1 shows mean nutrition delivered 
Table 1 STAR cohort patient demographics and GC perfor-
mance statistics
Data presented as median [IQR] where appropriate
Patient demographics
Number of patients 221
Number hours of GC 21,769
Age 64.0 [54.0–72.0]
Sex (% Male) 66.1
ICU length of stay 8.4 [3.1–15.3]
Days on GC 2.2 [1.2–3.9]
Admission to GC start (h) 17.5 [7.3–53.8]
Operative (%) 29.0
APACHE II score 21.0 [16.0–27.0]
ICU mortality (%) 28.0
GC performance statistics
BG mean per patient 6.66 [6.36–7.21]
BG SD per patient 1.17 [0.85–1.65]
% Time in targeted band (4.4–8.0 mmol/L) per 
patient
88.42 [77.42–94.44]
% Time in targeted band (4.4–8.0 mmol/L) cohort 83.2
% Time < 4.4 mmol/L cohort 1.35
# Patients < 2.2 mmol/L 4
Patients fed PN (%) 46.8
Mean days on PN 2.0 [1.0–5.8]
Mean PN per day (% caloric goal) 6.4 [1.5–14.5]
Table 2 Coefficients used to determine an ICU patients 
daily caloric goal in Christchurch ICU Hospital
Frame size (F) Small Medium Large
0.9 1.0 1.1
Age (A) ≤39 40–59 60–79 ≥80
1.1 1.0 0.9 0.8
Gender (G) Male Female
1.0 0.8
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to hyperglycaemic ICU patients by the variable nutri-
tion protocol in STAR performs very well compared to 
all ICU patients in the best ICU reviewed in Cahill et al., 
only slightly underperforming after day 3. It is well above 
the mean ICU surveyed on all days, as shown in Table 3. 
In addition, the mean percentage caloric goal nutrition, 
per day in ICU, exceeds the ‘Heyland ideal’ 85% caloric 
goal [51] from day 4 onwards.
Per‑patient nutrition delivery
Figure  2 shows the distribution of per-patient mean 
nutrition rates delivered per day by STAR, including IQR 
and 5th–95th percentile values. It clearly shows large var-
iation in patient-specific nutrition rates on the first day 
of ICU stay, which narrows as patient-specific metabolic 
state stabilises [21]. Table 3 shows over 56.2% of patients 
reach or exceed the ‘Heyland ideal’ 85% caloric goal in 
[51] after day 2, reaching 73.5% on day 7. The percent-
age of patients over the mean ICU result in [59] are also 
shown in Table  3 to be ranging from 100% on day 1 to 
85.7% on day 7. Overall, in comparison with Fig.  1, the 
per-patient results clearly show some patients cannot 
achieve this cohort mean rate or the ideal 100% caloric 
goal. As noted, the rates in Fig. 2 are an estimate of the 
‘STAR ideal’ time-varying patient-specific nutrition 
uptake in the context of GC to the 4.4-8.0  mmol/L BG 
range.
Table  4 shows the median of the mean feed rate 
achieved over a patient’s stay, per patient, is relatively 
high at 89.8% caloric goal, but has a large IQR of 23.9%. 
However, the relatively small median standard deviation 
of feed rate achieved over a patient’s stay, per patient, 
of 12.9% shows that individual patients are less variable 
than the cohort and thus that the overall ability to toler-
ate glucose is patient specific. Thus, it is clear the ability 
to take up, and thus to deliver, nutrition varies signifi-
cantly between GC patients.
Discussion
Overall clinical performance of current STAR variable 
nutrition protocol
Figure  1 shows STAR’s nutrition protocol, on hypergly-
caemic ICU patients, performs equal to or better than 
the average of all the ICU patients in the best ICU sur-
veyed by Cahill et al. [59] over the first 3 days of ICU stay. 
After day 3, the best ICU performs slightly better. How-
ever, the number of patients on GC is shown to diminish 
after day 3. This outcome makes the relevance of nutri-
tion performance less significant after this time. Overall, 
these outcomes show the current STAR nutrition pro-
tocol delivers clinical nutrition results for hyperglycae-
mic patients, which are equal to, or better than, those 
reported in the Cahill et al. survey for all ICU patients in 
158 ICUs in 20 countries. It is clear that high nutritional 
delivery and safe, effective GC are not mutually exclusive 
and that variable nutrition to achieve GC does not reduce 
total nutritional intake when compared to an entire ICU 
cohort.
Per‑patient nutrition delivery
Figure  2 shows a large variation in nutrition rates 
achieved per day, per patient, narrowing and rising as 
Fig. 1 (Top) Comparison of mean percentage goal feed achieved for 
each day in the ICU between STAR Christchurch clinical results and 
the results published in Cahill et al. The ‘Heyland ideal’ 85% caloric 
goal, to minimise mortality, presented in Heyland et al. [51] is also 
provided for comparison. (Bottom) The number of patients per day, 
where it is important to note that not all of the 221 patients start on 
day 1
Table 3 Percentage of patients above the Mean ICU reviewed by Cahill et al. [59] and ‘Heyland ideal’ rate of 85% [51]
Day in ICU Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
% Patients >
Mean Unit Cahill et al.
100.0 96.8 92.5 86.6 85.3 90.9 85.7
% Patients >
‘Heyland ideal’ (85%).
25.0 41.9 56.2 58.2 63.9 60.0 73.5
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the patient-specific metabolic state stabilises [21], similar 
to that seen in Heyland et al. [67]. However, the median 
variation per patient was only 12.9 [4.6–20.4] % (Table 4), 
suggesting patients do not deviate significantly from their 
mean nutrition rate. This result and the large IQR of the 
mean feed rates achieved (74.3–98.2%, Table  4) suggest 
the lower nutritional delivery to the 5th and 25th percen-
tile are a result of a few patients who had a lower ability 
to tolerate glucose intake.
It is very uncommon for patients not on GC in Christch-
urch ICU to have their feed rates changed due to the 
strong clinical culture of patients achieving their caloric 
goal. In addition, prior to STAR’s predecessor, SPRINT, 
being implemented (2005) [14], feed rates were fixed at 
100% caloric goal during GC for all patients. Hence, if 
they are not on GC, they are likely to have a fixed 100% 
caloric goal nutrition rate and have a BG within 4.4–
8.0 mmol/L, having a relatively constant glucose tolerance 
and reduced insulin sensitivity variability [21, 68]. There-
fore, if all patient data were considered, the intra-patient 
variability seen in Table 4 would likely go down.
Considering STAR feeds the maximum possible nutri-
tion, while safely maintaining normo-glycaemia, the 
nutrition rates achieved give a good indication of the 
patient-specific ability to tolerate glucose and thus of 
their ‘STAR ideal’ nutrition rate. In essence, every patient 
is fed the maximum they can achieve with added insu-
lin, within the bounds of the future predicted variability. 
Therefore, the spread of nutrition rates per patient in the 
results infer this ‘STAR ideal’ nutrition rate is very patient 
specific and evolves with time.
The ‘STAR ideal’ nutrition rate achieved by STAR was 
less than the 100% caloric goal for more than 50% of 
patients, over all days. However, the best unit surveyed 
in Cahill et al. [59] was still considerably lower than this 
predetermined caloric goal suggesting these generalised 
approximations do not represent all ICU patients well, as 
seen in the results for STAR in Christchurch. In addition, 
over 56% of patients exceeded the lower 85% ‘Heyland 
ideal’ of [51] by day 3, as shown in Table 3.
Limitations
Cahill et  al. [59] provides the percentage caloric goal 
nutrition achieved by each ICU. However, caloric goals 
may vary across ICUs. Additionally,  the estimation of 
patient body weight in Christchurch ICU [69], as shown 
in Table  2, may also bias the caloric goal feed esti-
mate which outlines the need for patients to be weighed 
on the day of ICU admission in Christchurch Hospital. 
As a result, some ICUs may thus achieve caloric goal 
nutrition targets ‘more easily’ than others, making com-
parison difficult. However, the 25  kcal/kg/day ACCP 
guideline [62] used in the Christchurch ICU, or a similar 
value guideline (25–30  kcal/kg/day SCCM/ASPEN [70], 
and 20–25  kcal/kgBW/day initial phase and recovery 
phase 25–30 kcal/kgBW/day ESPEN [71]), is commonly 
used and these cover the range used with STAR patients.
In addition, Cahill et al. review nutrition achieved during 
the first day of ICU stay, which is not necessarily when GC 
starts for all patients. Although GC commonly starts at the 
beginning of ICU stay, it may not always be the case. How-
ever, as an ICU patient is under the most amount of stress 
immediately post-surgery or insult [72], they are most likely 
to require GC at or near the beginning of their ICU stay [1–
3]. In this study, 59.3% of patients started GC within 24 h of 
being admitted to the ICU (Median 15.5 h, Table 1).
Moreover, Cahill et al. survey the nutrition given to all 
ICU patients. However, this study only considered patients 
who required GC. The 25–35% of patients who require GC 
in the ICU [28] are the most metabolically stressed and, 
as a result, have a reduced glucose uptake capacity. They 
Fig. 2 (Top) Comparison of the median interquartile range of STAR 
Christchurch’s percentage goal feed achieved clinically (N = 221 
Patients) and the best performing unit reviewed in Cahill et al. The 
‘Heyland ideal’ 85% caloric goal, to minimise mortality, presented 
in Heyland et al. [51] is also provided for comparison. (Bottom) The 
number of patients per day, where it is important to note that not all 
of the 221 patients start on day 1
Table 4 Per-patient feed rate characteristics
Data presented as median [IQR] where appropriate
Number of patients 221
Mean of a patient’s feed rate over entire stay, per 
patient (%)
89.8 [74.3–98.2]
SD of a patient’s feed rate over entire stay, per patient 
(%)
12.9 [4.6–20.4]
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are thus often harder to deliver the target nutrition rates 
[20, 52, 57, 58]. In addition, given that 158 ICUs over 20 
countries were surveyed by Cahill et al. [59], and this ICU 
was 1 of the 22 surveyed in Australia, and New Zealand 
the mixed medical surgical ICU in Christchurch Hospital 
would likely have patients with similar parameters. There-
fore, achieving nutrition rates with high performance 
GC similar to that achieved for all ICU patients, normo-
glycaemic and hyperglycaemic, in the best ICU reviewed 
by Cahill et al. [59] is a significant outcome. More impor-
tantly, this outcome and the inter-patient variability in the 
results indicate high nutrition delivery and safe, effective 
GC are not exclusive, an equally, that nutrition restriction 
to obtain GC does not necessarily reduce total nutrition in 
an international context.
The insulin–glucose model used by STAR has been 
shown to be effective in predicting a patient’s response [35, 
36, 73]. However, as STAR doses based on the 5th and 95th 
percentile future metabolic variability [38], ensuring only 
a 5% risk of hypoglycaemia [74], the majority of patient’s 
future BG will fall within the targeted band. Hence, many 
patients could possibly remain within the targeted BG 
range (4.4–8.0  mmol/L) if given a higher than recom-
mended nutrition rate. As a result, some patients may be 
able to receive higher nutrition rates than reported here 
and still be able to be provided effective GC. However, this 
choice would also increase the likelihood of hyperglycae-
mia, reducing the safety of GC provided by STAR.
The 85% caloric goal presented in Heyland et al. is cal-
culated by a model fit to retrospective data from 158 ICUs 
and clinical practices, and while it represents a significant 
body of multi-centre data, it may not be causative. Many 
prospective trials have found improved outcomes for 
even lower hypo-caloric feeding [50, 75–77]. Therefore, 
this ‘Heyland ideal’ value may overestimate the caloric 
goal required for improved outcomes and may be reflec-
tive of ‘less sick’ patients tolerating higher nutrition. This 
study is designed to show that STAR can provide high 
nutrition rates while still providing safe and effective GC. 
In addition, STAR is designed to be flexible to different 
nutrition goals while still providing effective GC.
Other factors, such as mechanical ventilation, neuro-
logic injury, gastric emptying and paresis patients, are 
well known to influence the nutritional requirements of 
ICU patients. This is another strong limitation of this 
retrospective analysis, as this detailed information was 
not available. However, the cohort was typical of medical 
ICU in Christchurch.
The STAR GC protocol uses model-based patient-
specific control in conjunction with a stochastic model 
to predict the best treatment for a patient. As shown in 
Table 1 and [32], STAR is able to achieve very good GC 
with a compliance of over 96.8% in all interventions and 
near identical results across multiple ICUs [32]. How-
ever, in many clinical practices, the idea of protocol-
driven changes in the nutrition given to a patient for GC 
is foreign and thus clinically unacceptable. Thus, the main 
focus of this study is to show that protocol-driven changes 
in nutrition rate do not preclude in achieving better nutri-
tion delivery rates than those of 158 ICUs from 20 coun-
tries. In addition, the concept of nutritional tolerances in 
relation to glucose tolerances provides a potentially new 
method of calculating patient-specific feed rates and 
should be investigated further in future studies.
Conclusions
The STAR GC protocol clinical provision of nutrition to 
hyperglycaemic patients was compared to nutrition rates 
of entire ICU cohorts surveyed in 158 ICUs in Cahill 
et al. [59]. Mean nutrition rates clinically achieved by the 
STAR variable nutrition protocol were significantly higher 
than the mean and best ICU surveyed, for the first 3 days 
of ICU stay. Overall, STAR’s protocol-driven changes 
in nutrition rate provide on average nutrition rates for 
hyperglycaemic patients which are equal to, or better than 
the mean of all ICU patients in 158 ICUs from 20 coun-
tries. More importantly, these outcomes show high nutri-
tion delivery and safe, effective GC are not exclusive and 
that restricting nutrition for GC does not limit overall 
nutritional intake compared to other ICUs.
The inter- and intra- patient variation of nutritional 
delivery was assessed in the STAR cohort There was large 
inter-patient variation in nutrition rates achieved per 
day, which reduced overtime as patient-specific meta-
bolic state stabilised. Median intra-patient variation was 
12.9%; however, the IQR of the mean per-patient nutri-
tion rates achieved was 74.3–98.2%, suggesting patients 
do not deviate much from their mean patient-specific 
nutrition rate and thus that the ability to tolerate glucose 
intake varies significantly between, rather than within, 
patients. There is significant inter-patient variability 
between patients to tolerate and uptake glucose, where 
intra-patient variability over stay is much lower. Thus, a 
best nutrition rate is likely patient specific for patients 
requiring GC.
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